Benchmark Maintains Buy on Ultralife, Raises Price Target to $13
Portfolio Pulse from Benzinga Newsdesk
Benchmark analyst Josh Sullivan maintains a Buy rating on Ultralife (NASDAQ:ULBI) and raises the price target from $12 to $13.

March 05, 2024 | 2:37 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Benchmark analyst Josh Sullivan reaffirms a Buy rating on Ultralife and increases the price target to $13.
The upgrade in the price target by a reputable analyst like Josh Sullivan suggests a positive outlook on Ultralife's stock, likely due to anticipated performance improvements or market conditions favoring the company. This can lead to increased investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100